SG11201608744VA - Improved methods for manufacturing adoptive cell therapies - Google Patents

Improved methods for manufacturing adoptive cell therapies

Info

Publication number
SG11201608744VA
SG11201608744VA SG11201608744VA SG11201608744VA SG11201608744VA SG 11201608744V A SG11201608744V A SG 11201608744VA SG 11201608744V A SG11201608744V A SG 11201608744VA SG 11201608744V A SG11201608744V A SG 11201608744VA SG 11201608744V A SG11201608744V A SG 11201608744VA
Authority
SG
Singapore
Prior art keywords
improved methods
adoptive cell
cell therapies
manufacturing
manufacturing adoptive
Prior art date
Application number
SG11201608744VA
Inventor
Richard Morgan
Kevin Friedman
Dawn Maier
Original Assignee
Bluebird Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54333268&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201608744V(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bluebird Bio Inc filed Critical Bluebird Bio Inc
Publication of SG11201608744VA publication Critical patent/SG11201608744VA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464411—Immunoglobulin superfamily
    • A61K39/464412—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464416—Receptors for cytokines
    • A61K39/464417—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2301—Interleukin-1 (IL-1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/855—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from receptors; from cell surface antigens; from cell surface determinants
SG11201608744VA 2014-04-25 2015-04-24 Improved methods for manufacturing adoptive cell therapies SG11201608744VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461984558P 2014-04-25 2014-04-25
PCT/US2015/027518 WO2015164745A1 (en) 2014-04-25 2015-04-24 Improved methods for manufacturing adoptive cell therapies

Publications (1)

Publication Number Publication Date
SG11201608744VA true SG11201608744VA (en) 2016-11-29

Family

ID=54333268

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201808258SA SG10201808258SA (en) 2014-04-25 2015-04-24 Improved methods for manufacturing adoptive cell therapies
SG11201608744VA SG11201608744VA (en) 2014-04-25 2015-04-24 Improved methods for manufacturing adoptive cell therapies

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201808258SA SG10201808258SA (en) 2014-04-25 2015-04-24 Improved methods for manufacturing adoptive cell therapies

Country Status (25)

Country Link
US (1) US20170051252A1 (en)
EP (2) EP3134095B1 (en)
JP (4) JP6817069B2 (en)
KR (3) KR101988614B1 (en)
CN (2) CN110819595A (en)
AU (2) AU2015249376C1 (en)
BR (1) BR112016024957A2 (en)
CA (1) CA2946552A1 (en)
CY (1) CY1123142T1 (en)
DK (1) DK3134095T3 (en)
ES (1) ES2800906T3 (en)
HR (1) HRP20200978T1 (en)
HU (1) HUE049514T2 (en)
IL (2) IL248349B (en)
LT (1) LT3134095T (en)
MX (2) MX370018B (en)
NZ (1) NZ725201A (en)
PL (1) PL3134095T3 (en)
PT (1) PT3134095T (en)
RS (1) RS60544B1 (en)
RU (1) RU2741899C2 (en)
SG (2) SG10201808258SA (en)
SI (1) SI3134095T1 (en)
WO (1) WO2015164745A1 (en)
ZA (2) ZA201607175B (en)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150064153A1 (en) 2013-03-15 2015-03-05 The Trustees Of Princeton University High efficiency microfluidic purification of stem cells to improve transplants
CA2942831A1 (en) 2013-03-15 2014-09-18 The Trustees Of Princeton University Methods and devices for high throughput purification
CN110186835B (en) 2013-03-15 2022-05-31 Gpb科学有限公司 On-chip microfluidic processing of particles
PL3132247T3 (en) 2014-04-16 2022-01-03 Juno Therapeutics Gmbh Methods, kits and apparatus for expanding a population of cells
CN113046312A (en) 2014-04-23 2021-06-29 朱诺治疗学股份有限公司 Methods of isolating, culturing and genetically engineering immune cell populations for adoptive therapy
CN106536549B (en) 2014-04-25 2020-01-17 蓝鸟生物公司 MND promoter chimeric antigen receptor
ES2846811T3 (en) 2014-06-06 2021-07-29 Bluebird Bio Inc Improved T cell compositions
JP6706244B2 (en) * 2014-07-24 2020-06-03 ブルーバード バイオ， インコーポレイテッド BCMA chimeric antigen receptor
EP3230441A4 (en) 2014-12-12 2018-10-03 Voyager Therapeutics, Inc. Compositions and methods for the production of scaav
SI3628687T1 (en) 2014-12-12 2021-12-31 2Seventy Bio, Inc. Bcma chimeric antigen receptors
KR20170093254A (en) 2014-12-29 2017-08-14 노파르티스 아게 Methods for producing chimeric antigen receptor-expressing cells
JP7114457B2 (en) 2015-04-17 2022-08-08 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア Methods for Improving Efficacy and Growth of Chimeric Antigen Receptor-Expressing Cells
CN107995913B (en) 2015-05-18 2022-02-11 T细胞受体治疗公司 Compositions and methods for reprogramming TCRs using fusion proteins
FR3038324B1 (en) 2015-06-30 2020-10-30 Lab Francais Du Fractionnement THERAPEUTIC-AIMED CELL CRYOPRESERVATION PROCESS
AR105433A1 (en) 2015-07-21 2017-10-04 Novartis Ag METHODS TO IMPROVE THE EFFECTIVENESS AND EXPANSION OF IMMUNE CELLS
US10976232B2 (en) 2015-08-24 2021-04-13 Gpb Scientific, Inc. Methods and devices for multi-step cell purification and concentration
TWI630934B (en) * 2015-10-14 2018-08-01 瑞典商神經毫微股份有限公司 Method and apparatus of implantation of a medical device into neural tissue
CN116875635A (en) 2015-10-22 2023-10-13 朱诺治疗学有限公司 Method, reagent cartridge, reagent and device for transduction
MA45489A (en) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh CELL CULTURE PROCESSES, ASSOCIATED KITS AND APPARATUS
JP2019502363A (en) 2015-10-30 2019-01-31 エヌビーイー セラピューティクス アクチェン ゲゼルシャフト Anti-ROR1 antibody
US11479755B2 (en) 2015-12-07 2022-10-25 2Seventy Bio, Inc. T cell compositions
CN117025539A (en) * 2015-12-28 2023-11-10 诺华股份有限公司 Method for preparing chimeric antigen receptor expressing cells
US20170233480A1 (en) 2015-12-31 2017-08-17 Development Center For Biotechnology Anti-vegfr antibody and uses thereof
SG11201806120WA (en) 2016-01-20 2018-08-30 Scripps Research Inst Ror1 antibody compositions and related methods
WO2017177137A1 (en) * 2016-04-07 2017-10-12 Bluebird Bio, Inc. Chimeric antigen receptor t cell compositions
CN108778312B (en) * 2016-04-08 2022-07-15 爱默蕾大学 Methods of treating cancer and infectious diseases using cell-based therapies
CN105907790A (en) * 2016-06-21 2016-08-31 林志国 Preparation method of CD70-contained chimeric antigen receptor modified T cell specifically recognizing EGFRvIII
CA3032498A1 (en) 2016-08-02 2018-02-08 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
IL302917A (en) 2016-10-07 2023-07-01 Tcr2 Therapeutics Inc Compositions and methods for t-cell receptors reprogramming using fusion proteins
EP3528630A4 (en) * 2016-10-21 2020-05-13 Georgia Tech Research Corporation Methods and systems for t cell expansion
CA3041522A1 (en) * 2016-10-24 2018-05-03 Gpb Scientific, Llc Deterministic lateral displacement in the preparation of cells and compositions for therapeutic uses
EP3544996A2 (en) 2016-11-22 2019-10-02 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
CA3043768A1 (en) 2016-11-29 2018-06-07 PureTech Health LLC Exosomes for delivery of therapeutic agents
US20190367876A1 (en) * 2017-01-18 2019-12-05 F1 Oncology, Inc. Methods of transducing and expanding immune cells and uses thereof
EP3577134A1 (en) 2017-01-31 2019-12-11 Novartis AG Treatment of cancer using chimeric t cell receptor proteins having multiple specificities
KR20190130608A (en) 2017-03-22 2019-11-22 노파르티스 아게 Compositions and Methods for Immune Oncology
CA3058425A1 (en) 2017-03-28 2018-10-04 The Trustees Of The University Of Pennsylvania Methods to protect transplanted tissue from rejection
WO2018201051A1 (en) 2017-04-28 2018-11-01 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
WO2018201056A1 (en) 2017-04-28 2018-11-01 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
CN109134660B (en) * 2017-06-16 2022-07-01 上海恒润达生生物科技股份有限公司 Methods of targeting chimeric antigen receptors of Mesothelin in combination with expression of anti-PD1 antibodies and uses thereof
CN107236762A (en) * 2017-06-19 2017-10-10 河北浓孚雨生物科技有限公司 A kind of method that minicircle dna transfecting T cells prepare clinical grade CAR T cell preparations
EP3648757A4 (en) * 2017-07-03 2020-11-25 Development Center for Biotechnology Anti-vegfr antibody and uses thereof
AU2018315127B2 (en) 2017-08-07 2021-12-23 Nbe-Therapeutics Ag Anthracycline-based antibody drug conjugates having high in vivo tolerability
ES2959953T3 (en) 2017-08-09 2024-02-29 Juno Therapeutics Inc Methods for producing genetically modified cellular compositions and related compositions
EP3675876A4 (en) * 2017-09-01 2021-06-02 GPB Scientific, Inc. Methods for preparing therapeutically active cells using microfluidics
CN114958772A (en) 2017-09-01 2022-08-30 隆萨沃克斯维尔股份有限公司 End-to-end cell therapy automation
TWI829655B (en) 2017-10-18 2024-01-21 瑞士商諾華公司 Compositions and methods for selective protein degradation
CN107893055B (en) * 2017-11-03 2020-07-17 深圳市默赛尔生物医学科技发展有限公司 Natural killer cell modified by specific chimeric antigen receptor gene and preparation method and application thereof
WO2019094835A1 (en) * 2017-11-10 2019-05-16 Juno Therapeutics, Inc. Closed-system cryogenic vessels
CN109776671B (en) * 2017-11-14 2022-05-27 杭州康万达医药科技有限公司 Isolated T cell receptor, modified cell thereof, encoding nucleic acid, expression vector, preparation method, pharmaceutical composition and application
JP2021502979A (en) 2017-11-15 2021-02-04 ノバルティス アーゲー BCMA targeting chimeric antigen receptor, CD19 targeting chimeric antigen receptor and combination therapy
KR20200096253A (en) 2017-11-30 2020-08-11 노파르티스 아게 BCMA-targeting chimeric antigen receptor, and uses thereof
MX2020005908A (en) * 2017-12-08 2020-10-07 Juno Therapeutics Inc Process for producing a composition of engineered t cells.
CN109609533B (en) * 2017-12-27 2020-07-10 赛德特生物科技开发有限公司 CAR lentivirus expression vector construction based on humanized CD276 antibody and application thereof
CN112218651A (en) 2018-01-08 2021-01-12 诺华公司 Immunopotentiating RNA for combination with chimeric antigen receptor therapy
CN112125976B (en) * 2018-01-26 2022-06-03 重庆精准生物技术有限公司 Modified hinge and application thereof in constructing CAR framework
US20210038659A1 (en) 2018-01-31 2021-02-11 Novartis Ag Combination therapy using a chimeric antigen receptor
BR112020016176A2 (en) * 2018-02-09 2022-02-22 Immatics Us Inc Methods of transducing a t cell, genetically transduced t cell, pharmaceutical composition, methods of preparing a population of t cells and using the t cell
DE102018108996B4 (en) 2018-02-09 2021-10-21 Immatics US, Inc. Process for the production of autologous T cells
WO2019160956A1 (en) 2018-02-13 2019-08-22 Novartis Ag Chimeric antigen receptor therapy in combination with il-15r and il15
CN110272481A (en) * 2018-03-14 2019-09-24 中国科学院广州生物医药与健康研究院 Identify the T cell receptor of MAGE1 antigen small peptide
EP3765121A4 (en) * 2018-03-14 2021-12-22 Thermogenesis Corp. Buoyancy-activated cell sorting (bacs)-compatible activation/transduction systems and methods
DE102018108612A1 (en) 2018-03-21 2019-09-26 Immatics US, Inc. METHOD FOR INCREASING PERSISTENCE OF ADOPTIVELY INFUNDED T CELLS
KR20210005138A (en) 2018-04-27 2021-01-13 이오반스 바이오테라퓨틱스, 인크. Closure method for expansion and gene editing of tumor infiltrating lymphocytes and their use in immunotherapy
CN112424342A (en) * 2018-05-08 2021-02-26 生命科技公司 Compositions and methods for culturing and expanding cells
CN108929862A (en) * 2018-08-01 2018-12-04 上海市第人民医院 A kind of the T cell preparation and amplification method and its application of malignant tumour Lung metastases companion malignant pleural effusion
WO2020047449A2 (en) 2018-08-31 2020-03-05 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
EP3844267A2 (en) 2018-08-31 2021-07-07 Novartis AG Methods of making chimeric antigen receptor-expressing cells
MX2021005372A (en) 2018-11-08 2021-09-14 Neximmune Inc T cell compositions with improved phenotypic properties.
MX2021005721A (en) * 2018-11-16 2021-07-21 Celgene Corp Improved t cell manufacturing process.
WO2020106621A1 (en) * 2018-11-19 2020-05-28 Board Of Regents, The University Of Texas System A modular, polycistronic vector for car and tcr transduction
KR20210107749A (en) 2018-12-21 2021-09-01 옥테인 바이오테크 인코포레이티드 Carousel for modular biological production units
US11718833B2 (en) 2018-12-21 2023-08-08 Lonza Walkersville, Inc. Automated production of viral vectors
KR20210125510A (en) 2019-02-08 2021-10-18 론자 워커스빌 아이엔씨. Cell Concentration Methods and Apparatus for Use in Automated Bioreactors
EP3930763A1 (en) 2019-02-25 2022-01-05 Novartis AG Mesoporous silica particles compositions for viral delivery
US20200297768A1 (en) * 2019-03-19 2020-09-24 Immatics US, Inc. Cd28 t cell cultures, compositions, and methods of using thereof
WO2020191316A1 (en) 2019-03-21 2020-09-24 Novartis Ag Car-t cell therapies with enhanced efficacy
EP3945815A4 (en) * 2019-04-03 2023-04-19 Akron Biotechnology, LLC Cryopreservation and cell culture media
EP3946355A4 (en) * 2019-04-05 2023-05-10 2seventy bio, Inc. Manufacturing anti-bcma car t cells
EP3953455A1 (en) 2019-04-12 2022-02-16 Novartis AG Methods of making chimeric antigen receptor-expressing cells
WO2020219742A1 (en) 2019-04-24 2020-10-29 Novartis Ag Compositions and methods for selective protein degradation
WO2021041399A1 (en) * 2019-08-29 2021-03-04 Board Of Regents, The University Of Texas System Cell cryopreservation medium
WO2021062267A1 (en) * 2019-09-26 2021-04-01 Nantbio, Inc. Primary t-cell expansion
CN110747166B (en) * 2019-10-11 2021-07-09 厦门大学 In-vitro amplification culture method for peripheral blood T cells
EP4065158A2 (en) 2019-11-26 2022-10-05 Novartis AG Chimeric antigen receptors binding bcma and cd19 and uses thereof
CA3173394A1 (en) * 2020-02-27 2021-09-02 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
EP4110377A2 (en) 2020-02-27 2023-01-04 Novartis AG Methods of making chimeric antigen receptor-expressing cells
CN115997008A (en) * 2020-04-22 2023-04-21 艾欧凡斯生物治疗公司 Systems and methods for coordinating the manufacture of cells for patient-specific immunotherapy
EP4165169A1 (en) 2020-06-11 2023-04-19 Novartis AG Zbtb32 inhibitors and uses thereof
WO2022040586A2 (en) 2020-08-21 2022-02-24 Novartis Ag Compositions and methods for in vivo generation of car expressing cells
TW202309294A (en) 2021-04-27 2023-03-01 瑞士商諾華公司 Viral vector production system
CA3229746A1 (en) * 2021-08-20 2023-02-23 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
CN114317435B (en) * 2021-12-30 2024-02-27 杭州芯递力生物科技有限公司 Method for obtaining antigen-specific T cells
WO2023230512A1 (en) 2022-05-26 2023-11-30 2Seventy Bio, Inc. Compositions for maintaining lentiviral vector and uses thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
US6905680B2 (en) * 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
ES2162823T5 (en) 1992-08-21 2010-08-09 Vrije Universiteit Brussel IMMUNOGLOBULINS DESPROVISTAS OF LIGHT CHAINS.
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
AU6796094A (en) 1993-04-29 1994-11-21 Raymond Hamers Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of (camelidae)
AU726198B2 (en) * 1996-03-04 2000-11-02 Targeted Genetics Corporation Modified rapid expansion methods ("modified-REM") for in vitro propagation of T lymphocytes
FR2777909B1 (en) 1998-04-24 2002-08-02 Pasteur Institut USE OF TRIPLEX-STRUCTURED DNA SEQUENCES FOR THE TRANSFER OF NUCLEOTID SEQUENCES IN CELLS, RECOMBINANT VECTORS CONTAINING THESE TRIPLEX SEQUENCES
WO2001062895A2 (en) * 2000-02-24 2001-08-30 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
EP1385946B1 (en) 2001-05-01 2009-12-23 National Research Council Of Canada A system for inducible expression in eukaryotic cells
WO2003057171A2 (en) 2002-01-03 2003-07-17 The Trustees Of The University Of Pennsylvania Activation and expansion of t-cells using an engineered multivalent signaling platform
GB0224442D0 (en) * 2002-10-21 2002-11-27 Molmed Spa A delivery system
MXPA05012080A (en) * 2003-05-08 2006-02-22 Xcyte Therapies Inc Generation and isolation of antigen-specific t cells.
WO2005118788A2 (en) * 2004-05-27 2005-12-15 The Trustees Of The University Of Pennsylvania Novel artificial antigen presenting cells and uses therefor
CN101238218A (en) 2005-05-20 2008-08-06 维克西斯公司 Transduction of primary cells
CA2687688C (en) * 2007-05-23 2017-03-28 Sangamo Biosciences, Inc. Methods and compositions for increased transgene expression in t cells
SI2496698T1 (en) 2009-11-03 2019-07-31 City Of Hope TRUNCATED EPIDERIMAL GROWTH FACTOR RECEPTOR (EGFRt) FOR TRANSDUCED T CELL SELECTION
KR102062407B1 (en) 2010-12-09 2020-01-03 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Use of chimeric antigen receptor-modified t cells to treat cancer
JP2014514927A (en) * 2011-04-13 2014-06-26 イミュニカム・エイビイ Method for the proliferation of antigen-specific T cells
CN104159909A (en) * 2012-02-22 2014-11-19 宾夕法尼亚大学董事会 Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer
CA2869562C (en) 2012-04-11 2023-09-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric antigen receptors targeting b-cell maturation antigen
US20130280220A1 (en) 2012-04-20 2013-10-24 Nabil Ahmed Chimeric antigen receptor for bispecific activation and targeting of t lymphocytes
AU2013312838B2 (en) * 2012-09-04 2018-11-29 Cellectis Multi-chain chimeric antigen receptor and uses thereof
EP2711418B1 (en) 2012-09-25 2017-08-23 Miltenyi Biotec GmbH Method for polyclonal stimulation of T cells by flexible nanomatrices
WO2014055442A2 (en) * 2012-10-01 2014-04-10 The Trustees Of The University Of Pennsylvania Compositions and methods for targeting stromal cells for the treatment of cancer
ES2824024T3 (en) * 2012-10-10 2021-05-11 Sangamo Therapeutics Inc T cell modifying compounds and uses thereof
WO2014099671A1 (en) 2012-12-20 2014-06-26 Bluebird Bio, Inc. Chimeric antigen receptors and immune cells targeting b cell malignancies

Also Published As

Publication number Publication date
CN106456670A (en) 2017-02-22
JP2022040287A (en) 2022-03-10
MX2016013963A (en) 2017-06-12
EP3134095B1 (en) 2020-04-22
EP3134095A1 (en) 2017-03-01
IL248349B (en) 2020-08-31
CA2946552A1 (en) 2015-10-29
KR20190066089A (en) 2019-06-12
AU2015249376A1 (en) 2016-11-03
BR112016024957A2 (en) 2017-10-24
JP2020015767A (en) 2020-01-30
SG10201808258SA (en) 2018-10-30
HRP20200978T1 (en) 2020-10-16
CY1123142T1 (en) 2021-10-29
NZ725201A (en) 2018-05-25
CN106456670B (en) 2020-01-07
ZA201902286B (en) 2022-08-31
KR102161927B1 (en) 2020-10-06
MX2019014009A (en) 2020-02-05
PL3134095T3 (en) 2020-10-19
IL248349A0 (en) 2016-11-30
EP3738597A1 (en) 2020-11-18
KR20180105733A (en) 2018-09-28
US20170051252A1 (en) 2017-02-23
WO2015164745A1 (en) 2015-10-29
SI3134095T1 (en) 2020-08-31
AU2018203687A1 (en) 2018-06-21
JP2017513891A (en) 2017-06-01
RU2016145968A3 (en) 2018-11-13
KR20160141865A (en) 2016-12-09
JP7012056B2 (en) 2022-02-10
DK3134095T3 (en) 2020-06-29
JP6817069B2 (en) 2021-01-20
LT3134095T (en) 2020-06-10
KR101988614B1 (en) 2019-06-12
RS60544B1 (en) 2020-08-31
RU2016145968A (en) 2018-05-28
IL276593A (en) 2020-09-30
MX370018B (en) 2019-11-28
ES2800906T3 (en) 2021-01-05
EP3134095A4 (en) 2017-09-20
PT3134095T (en) 2020-07-02
IL276593B (en) 2021-10-31
JP2018087254A (en) 2018-06-07
AU2018203687C1 (en) 2022-01-13
AU2018203687B2 (en) 2019-03-21
HUE049514T2 (en) 2020-09-28
RU2741899C2 (en) 2021-01-29
ZA201607175B (en) 2022-08-31
CN110819595A (en) 2020-02-21
AU2015249376C1 (en) 2019-10-31
AU2015249376B2 (en) 2018-03-08

Similar Documents

Publication Publication Date Title
IL276593B (en) Improved methods for manufacturing adoptive cell therapies
IL274903A (en) Cell
HK1244826A1 (en) Methods and compositions for adoptive cell therapy
IL250072A0 (en) Engineered cells for adoptive cell therapy
SG11201703493SA (en) Cell culture insert
EP3036639A4 (en) Storage cluster
SG11201701369VA (en) Separator for battery
HK1248555A1 (en) Selection methods for genetically-modified t cells
EP3233097A4 (en) Improved cell therapies
HUE042287T2 (en) Lithium-sulphur cell
GB201413781D0 (en) Fuel cell
GB201411625D0 (en) Fuel cell
SG10201403640XA (en) Stem cells
IL248910B (en) Cell tray
AU2014905156A0 (en) Improved cell therapies
GB201413395D0 (en) Cell separation methods
GB201421342D0 (en) Cell culture
GB201410934D0 (en) T cell
GB201420088D0 (en) Battery modules and methods for their manufacture
AU362175S (en) Battery pack
GB201416750D0 (en) Cell preparation
GB201401068D0 (en) Cell maturation process